Olumiant 2 mg film-coated tablets clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct)
This study is looking at a new treatment called Baricitinib for people admitted to hospital with COVID-19. It aims to see if it can stop people from getting sicker or dying, compared to a dummy treatment.
For: SARS-CoV II infection (Coronavirus disease)Norway · Portugal · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1)
This study is looking at a new treatment called Olumiant for polymyalgia rheumatica. It aims to see if Olumiant can help people get better and reduce their need for steroid medications, which often have side effects. Researchers are checking how well it works and if it's safe.
For: polymyalgia rheumaticaAustria · Czechia · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE)
This study is looking at a new tablet treatment called baricitinib (Olumiant) for a type of eye inflammation called uveitis. Researchers want to see if it can help improve symptoms and reduce the need for other medications over six months.
For: Active non-anterior non-infectious uveitisFrance